Clavita Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 23-10-2024
- Paid Up Capital ₹ 0.10 M
as on 23-10-2024
- Company Age 10 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.40 M
as on 23-10-2024
- Revenue 54.53%
(FY 2023)
- Profit 663.46%
(FY 2023)
- Ebitda 74.17%
(FY 2023)
- Net Worth 120.04%
(FY 2023)
- Total Assets -7.37%
(FY 2023)
About Clavita Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹2.40 M.
Subrahmanya Jampana and Anuradha Jampana serve as directors at the Company.
- CIN/LLPIN
U24230AP2014PTC093698
- Company No.
093698
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Mar 2014
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Vijayawada
Industry
Company Details
- Location
Visakhapatnam, Andhra Pradesh, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Clavita Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Subrahmanya Jampana  | Director | 21-Mar-2014 | Current |
| Anuradha Jampana | Additional Director | 26-Mar-2018 | Current |
Financial Performance of Clavita Pharma.
Clavita Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 54.53% increase. The company also saw a substantial improvement in profitability, with a 663.46% increase in profit. The company's net worth Soared by an impressive increase of 120.04%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Clavita Pharma?
In 2023, Clavita Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Lifecare Laboratories Private LimitedActive 21 years 7 monthsSubrahmanya Jampana and Anuradha Jampana are mutual person
Jampana Farms Private LimitedActive 7 years 10 monthsSubrahmanya Jampana and Anuradha Jampana are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Canara Bank Creation Date: 22 Jul 2021 | ₹2.40 M | Open |
How Many Employees Work at Clavita Pharma?
Clavita Pharma has a workforce of 28 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Clavita Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Clavita Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
